- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.07. | Nasus Pharma Appoints Brendan O'Grady As CEO, Succeeding Dan Teleman | 1 | RTTNews | ||
| 28.07. | Nasus Pharma Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 28.07. | Nasus Pharma names Brendan O'Grady as new CEO | 1 | Investing.com | ||
| 28.07. | Nasus Pharma, Ltd.: Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth | 219 | GlobeNewswire (Europe) | TEL AVIV, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus", "Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of... ► Artikel lesen | |
| NASUS PHARMA Aktie jetzt für 0€ handeln | |||||
| 09.06. | Nasus Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 09.06. | Nasus Pharma reports positive preclinical data for NS003 | 1 | Investing.com | ||
| 26.05. | Nasus Pharma Ltd - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 26.03. | Citizens senkt Kursziel für Nasus Pharma auf 18 US-Dollar | 1 | Investing.com Deutsch | ||
| 26.03. | Citizens cuts Nasus Pharma stock price target to $18 on valuation | 1 | Investing.com | ||
| 25.03. | Nasus Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 25.03. | Nasus Pharma legt positive Phase-2-Daten für Adrenalin-Nasenspray vor | 1 | Investing.com Deutsch | ||
| 25.03. | Nasus Pharma reports Phase 2 results for intranasal epinephrine | 1 | Investing.com | ||
| 25.03. | Nasus Pharma Ltd - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings | ||
| 25.03. | Nasus Pharma, Ltd.: Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update | 250 | GlobeNewswire (Europe) | Recent Phase 2 topline results demonstrate NS002's potential for best-in-class epinephrine delivery, with statistically significant improvements in early absorption compared to EpiPen®; pivotal study... ► Artikel lesen | |
| 18.03. | What's Going On With Nasus Pharma Stock On Wednesday | 1 | Benzinga.com | ||
| 16.03. | Nasus Pharma Stock Hits 52-Week Low - Here's Why | 4 | Benzinga.com | ||
| 16.03. | Nasus Pharma Ltd - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 16.03. | Nasus Pharma reports faster epinephrine delivery in Phase 2 study | 1 | Investing.com | ||
| 16.03. | Nasus Pharma, Ltd.: Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen with Accelerated Speed to Therapeutic Threshold | 276 | GlobeNewswire (Europe) | NS002 demonstrated significantly faster time to the critical 100 pg/mL epinephrine threshold compared to EpiPen®, with a median T100 of 1.69 minutes versus 3.42 minutes (p=0.033). At 5 minutes, 88.4%... ► Artikel lesen | |
| 09.03. | Nasus Pharma to present phase 2 data for intranasal epinephrine | 1 | Investing.com |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QUANTUM BIOPHARMA | 2,912 | +12,35 % | Quantum BioPharma Announces Closing of Debt Settlement | THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, July 30, 2026... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 66,00 | -0,15 % | Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis | Two global registrational Phase 3 trials initiated in ZENITH AD program
Phase 3 program based upon clinically meaningful efficacy and favorable safety data observed... ► Artikel lesen | |
| ORAMED PHARMACEUTICALS | 3,670 | -0,54 % | Oramed Pharmaceuticals Inc.: Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet | Significant Appreciation in Alpha Tau (NASDAQ: DRTS) Position (up ~$128 Million)
Scilex (NASDAQ: SCLX) Loan Substantially Repaid
Total Cash and Assets Build... ► Artikel lesen | |
| OPKO HEALTH | 1,130 | -1,74 % | Cocrystal Pharma, Inc.: Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health | Longtime investor OPKO Health increases its position as Cocrystal advances toward norovirus Phase 1b data in late 2026 BOTHELL, Wash., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq:... ► Artikel lesen | |
| OPUS GENETICS | 3,100 | 0,00 % | Opus Genetics, Inc.: Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update | OPGx-BEST1 Cohort 1 Topline Data Expected in Second Week of September 2026 Enrollment Completed in LCA5 Registrational Trial with Dosing Planned for Q4 2026 RDH12, MERTK and RHO Programs Advancing... ► Artikel lesen | |
| PROTHENA | 7,570 | 0,00 % | Prothena Corporation plc: Prothena Reports Second Quarter 2026 Financial Results and Business Highlights | Net cash used in operating and investing activities was $25.7 million in the second quarter and net cash provided by operating and investing activities was $3.2 million for the first six months... ► Artikel lesen | |
| NRX PHARMACEUTICALS | 3,035 | -1,94 % | NRx Pharmaceuticals, Inc.: FDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval | FDA identified no major deficiencies related to the ketamine drug product, ingredients, proposed labeling, CMC, or other drug-related review matters.Remaining item relates to manufacturer certification... ► Artikel lesen | |
| NEUROGENE | 30,000 | -1,32 % | Morning Market Movers: Neurogene, Duolingo, Xponential Fitness, Emergent BioSolutions See Big Swings | WASHINGTON (dpa-AFX) - At 6:22 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ORIC PHARMACEUTICALS | 11,420 | -2,10 % | ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | ||
| REVIVA PHARMACEUTICALS | 0,351 | -0,20 % | Reviva Pharmaceuticals: Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights | - Composition of matter provisional patent application filed for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 - - FDA feedback on use of new form... ► Artikel lesen | |
| OMNIAB | 3,080 | 0,00 % | OmniAb GAAP EPS of -$0.05 beats by $0.07, revenue of $13.4M beats by $8.71M | ||
| ONKURE THERAPEUTICS | 4,120 | -0,48 % | OnKure Therapeutics, Inc.: OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | -- Executing IND-enabling activities for next-generation PI3Ka pan-mutant selective candidates OKI-345 in breast cancer and OKI-355 in vascular anomalies, with IND submissions planned for 1H 2027... ► Artikel lesen | |
| PROCESSA PHARMACEUTICALS | 2,600 | +1,17 % | Processa Acquisition Lands Immunology Drug That Could Rival a New Novartis Product | ||
| PRF TECHNOLOGIES | 1,050 | +0,96 % | PRF Technologies Ltd.: PRF Technologies Issues Letter to Shareholders Highlighting Strengthened Financial Position and Building Momentum Across Its Biotechnology and AI-Driven Energy Platforms | TEL AVIV, Israel, July 27, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (Nasdaq: PRFX) ("PRF", "PRF Technologies" or the "Company") today issued a Letter to Shareholders from Efraim Cohen-Arazi... ► Artikel lesen | |
| ANBIO BIOTECHNOLOGY | 9,000 | -5,76 % | Anbio Biotechnology - 6-K, Report of foreign issuer |
NASUS PHARMA LTD gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 3,450 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NASUS PHARMA LTD finden Sie auf Wallstreet Online.